First Knee+ AR Surgery in the USA for Pixee Medical

Pixee Medical, a pioneer in digitally augmented surgery technology, announces that Dr Antonia Chen performed the first Knee+ surgeries in the USA at the Brigham and Women’s Hospital in Boston (MA).

Knee+ is a patented platform designed to help orthopedic surgeons perform Total Knee Replacement surgeries by providing real-time 3D positioning of instruments, right in their field of view. Knee+ is intuitive and requires minimal training since it does not change the overall workflow for surgeons. Knee+ consists in a proprietary software using unique computer vision algorithms and running on augmented reality smart glasses, without bulky capital equipment or disposables required.

After the first Knee+ surgery in June 2020 in Lariboisière Hospital (Paris, France), Pixee Medical began commercialization in Europe and Australia in January 2021 and was surprised how quickly its product was easily adopted. With more than 100 systems sold, the company proved that the market was ready for this innovation and is now expanding rapidly by partnering with leading orthopedic implant companies.

“This first surgery in the USA is an important milestone for Pixee Medical as the country represents 50% of the worldwide market and more than 800 000 TKR a year. Today, Knee+ is well suited to help ambulatory surgical centers (ASC) face the significant increase in knee surgery. These centers need intuitive, effective, attractive, and affordable solutions to meet their patient’s needs, now.” said Sébastien Henry, Founder and CEO of Pixee Medical.

“I have been impressed by the efficiency of the system. The product works well and flows nicely” commented Dr Antonia Chen, first surgeon to perform a Total Knee Arthroplasty using Knee+ augmented surgery in the USA. “The product doesn’t need a big equipment and offers an easy and efficient way to achieve a plan compared to robotics and other more traditional navigation systems. You can perform a TKR with only a small set of reusable instruments and essential information in your field of view. This is probably the most cost-effective solution for ASC”.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”